BUNAVAIL PDUFA date is June 7, 2014.
Positive Phase III top-line results reported for BEMA Buprenorphine.
2013 R&D expense was $53.3M ($41.8M for BEMA).
Net loss was $57.4M (-$1.51/share) due to higher R&D costs.
Cash balance as of February 28 was $89.8M.
Preparations being made for the Q3 launch of BUNAVAIL.
Second database lock for BEMA Phase III clinical trial to occur at mid-year triggering a $10M milestone payment from Endo International (ENDP). NDA to be filed in late 2014 or early 2015.
Phase III trial for Clonidine Topical Gel commences by end of March. Interim data may be available by year end.
Consensus revenue estimates for 2014 and 2015 are $13.5M and $31.5M, respectively.
112 mutual funds have positions, up from 99 a year earlier.